SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Miscellaneous > Rigel Pharmaceuticals Inc. (RIGL)

7:40AM On The Wires (WIRES) :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 423
Posts 22,958
Boards Moderated 5
Alias Born 09/11/06
160x600 placeholder
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares "PR Newswire (US)" - 10/10/2017 4:01:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/5/2017 5:31:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/5/2017 5:23:13 PM
Rigel Announces Pricing Of Public Offering Of Common Stock "PR Newswire (US)" - 10/4/2017 10:36:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/3/2017 4:11:42 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/3/2017 4:08:40 PM
Rigel Announces Proposed Public Offering Of Common Stock "PR Newswire (US)" - 10/3/2017 4:01:00 PM
Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study "PR Newswire (US)" - 10/3/2017 7:30:00 AM
Rigel Provides Update on FDA Review of Fostamatinib for ITP "PR Newswire (US)" - 10/2/2017 7:30:00 AM
Rigel to Present at Cantor Fitzgerald Global Healthcare Conference "PR Newswire (US)" - 9/19/2017 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/25/2017 5:00:39 PM
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors "PR Newswire (US)" - 8/25/2017 7:30:00 AM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) "PR Newswire (US)" - 8/18/2017 4:02:00 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 8/1/2017 4:28:42 PM
Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update "PR Newswire (US)" - 8/1/2017 4:27:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/1/2017 4:12:14 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/1/2017 4:04:25 PM
Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results "PR Newswire (US)" - 7/25/2017 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/7/2017 5:40:07 PM
Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology As... "PR Newswire (US)" - 6/22/2017 4:05:00 PM
FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP "PR Newswire (US)" - 6/19/2017 7:30:00 AM
Breakfast Technical Briefing on Generic Drugs Stocks -- Innocoll, Rigel Pharma, Tetraphase Pharma, and Catalent "PR Newswire (US)" - 6/5/2017 6:10:00 AM
Rigel to Present at Jefferies 2017 Global Healthcare Conference "PR Newswire (US)" - 6/1/2017 7:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 5/30/2017 4:30:18 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/30/2017 4:18:11 PM
surf1944   Friday, 05/06/11 09:58:11 AM
Re: surf1944 post# 130
Post # of 430 
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.



surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist